Evidence map›Paper›PMID 37398302›Full record

ArticleResearch square2023

Peripheral MC1R activation modulates immune responses and is neuroprotective in a mouse model of Parkinson's disease.

Pranay Srivastava, Shuhei Nishiyama, Sonia H Lin, Akriti Srivastava, Chienwen Su, Weiyi Peng, Michael Levy, Michael Schwarzschild, Yuehang Xu, Xiqun Chen

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in Research square, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Pranay SrivastavaMassGeneral Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital, Harvard Medical School.
Shuhei NishiyamaMassGeneral Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital, Harvard Medical School.
Sonia H LinMassGeneral Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital, Harvard Medical School.
Akriti SrivastavaMassGeneral Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital, Harvard Medical School.
Chienwen SuMassGeneral Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital, Harvard Medical School.
Weiyi PengDepartment of Biology and Biochemistry, University of Houston.
Michael LevyMassGeneral Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital, Harvard Medical School.
Michael SchwarzschildMassGeneral Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital, Harvard Medical School.
Yuehang XuMassGeneral Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital, Harvard Medical School.
Xiqun ChenMassGeneral Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital, Harvard Medical School.
Harvard University · US

Funding

Urate-LRRK2 interactions in Parkinson's diseaseR01NS110879 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI SCHWARZSCHILD, MICHAEL A · 2019 to 2023
$2.0M
MC1R Basis of Melanoma-Parkinson's Link and Neuroprotective Potential of MC1RR01NS102735 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI CHEN, XIQUN · 2018 to 2022
$1.8M
NINDS NIH HHS R01 NS102735NINDS NIH HHS R01 NS110879
6 · The paper itself

Abstract

Background: Melanocortin 1 receptor ( Methods: C57BL/6 mice were treated systemically with MPTP Results: Systemic NDP-MSH administration significantly attenuated striatal dopamine depletion and nigral dopaminergic neuron loss induced by MPTP+LPS. It improved the behavioral outcomes in the pole test. Conclusions: Our study demonstrates that peripherally acting NDP-MSH confers protection on dopaminergic nigrostriatal neurons and reduces hyperactivated microglia. NDP-MSH modulates peripheral immune responses, and Tregs may be involved in the neuroprotective effect of NDP-MSH.

Indexed as

BBBLPSMelanocortin 1 receptorMPTPParkinson’s diseaseRegulatory T cells (Tregs)

Identifiers

PMID37398302
PMCPMC10312952
OpenAlexW4380320060

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.